Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in Spain: the MERENA observational cohort study - Test2 - elhamkhani - TriplyDB

Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in Spain: the MERENA observational cohort study

Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in Spain: the MERENA observational cohort study

http://www.wikidata.org/entity/Q34039724

about

Lanthanum carbonate for the control of hyperphosphatemia in chronic renal failure patients: a new oral powder formulation - safety, efficacy, and patient adherence Baseline Characteristics and Prescription Patterns of Standard Drugs in Patients with Angiographically Determined Coronary Artery Disease and Renal Failure (CAD-REF Registry)Human Heredity and Health (H3) in Africa Kidney Disease Research Network: A Focus on Methods in Sub-Saharan Africa Suboptimal blood pressure control in chronic kidney disease stage 3: baseline data from a cohort study in primary care.Improving CKD Diagnosis and Blood Pressure Control in Primary Care: A Tailored Multifaceted Quality Improvement Programme.Markers of increased cardiovascular risk in patients with chronic kidney disease.Baseline characteristics and prevalence of cardiovascular disease in newly visiting or referred chronic kidney disease patients to nephrology centers in Japan: a prospective cohort study.Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction.Emerging drug combinations to optimize renovascular protection and blood pressure goals.Prevalence and risk factors for cardiovascular disease among chronic kidney disease patients: results from the Chinese cohort study of chronic kidney disease (C-STRIDE).Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study.Reduced plasma ACE2 activity in dialysis patients: another piece in the conundrum of factors involved in hypertension and cardiovascular morbidity?ACE2 alterations in kidney disease.Prevalence and management of anemia in pre-dialysis Malaysian patients: A hospital-based study.Definitions of progression in chronic kidney disease--predictors and relationship to renal replacement therapy in a population cohort with a 6 year follow-up.Anaemia management in non-dialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics.Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study.Blood pressure control in chronic kidney disease: A cross-sectional analysis from the German Chronic Kidney Disease (GCKD) study

P2860

Q27013882-0D974E89-D9CB-493E-BEB5-88CE101FCD78 Q28550033-88DACF3B-3CE9-4274-959C-8948C17D4196 Q28606687-AC5110C0-2A5A-44B4-8A50-461E2E6B4016 Q30651585-45C2111B-377E-4D34-8841-9F4FE6FC68DB Q33652413-2F2D7603-1320-4F2A-8042-46BBFE4157E0 Q34582124-47CFCB89-2439-444C-B5C8-75B22023B8F5 Q34831465-059B36CC-18B3-4ACA-9AF7-14D1701819E9 Q35407690-026112A4-C286-43EB-800B-EB279476E7C9 Q35905899-D1E13069-7783-4112-82E9-EAE774AEF877 Q36249768-D76FAA99-3629-4DDF-8D36-9D32B1714AEF Q36538088-F0A28AFD-7010-4A35-AC89-C8231C2DF9C1 Q37162741-C66C35E1-F26F-4201-882B-921D57647FA3 Q37262837-BECA4794-BC2C-45F2-8DCF-83F1A7942ECE Q40418454-3E766FE8-EC8C-497E-8FC9-B782D1C1B84F Q44608520-B5430E62-49F4-4A64-B0A5-ACADE78295AA Q44927431-A266976B-52CB-41A2-832D-287B9D5EAE1E Q53501050-DF815870-E36A-482F-B239-8EC9C7E090C0 Q58765668-54EAEB5F-7B50-422C-B87F-34DF56BF489C

P2860

Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in Spain: the MERENA observational cohort study

http://www.wikidata.org/entity/Q34039724

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Baseline characteristics of pa ...... ENA observational cohort study

@ast

Baseline characteristics of pa ...... ENA observational cohort study

@en

Baseline characteristics of pa ...... ENA observational cohort study

@nl

type

label

Baseline characteristics of pa ...... ENA observational cohort study

@ast

Baseline characteristics of pa ...... ENA observational cohort study

@en

Baseline characteristics of pa ...... ENA observational cohort study

@nl

prefLabel

Baseline characteristics of pa ...... ENA observational cohort study

@ast

Baseline characteristics of pa ...... ENA observational cohort study

@en

Baseline characteristics of pa ...... ENA observational cohort study

@nl

P1433

Q34039724-4EBFC499-92BC-48A5-9579-29B2D6E37FC8

P1476

Q34039724-38DE062E-0D81-4708-AE06-834DCFEA91BE

P2093

Q34039724-0BB199EC-8153-499A-AC4F-7F904091083D

Q34039724-35AE59ED-DFFE-4B7B-A208-26441AF74B7D

Q34039724-37CC9547-3B71-4E78-BDFB-F175219293BB

Q34039724-4A993EF5-F0B2-417E-BD1D-75971EFDE837

Q34039724-519FDCA9-0A84-4BFD-9F0F-A473BF0C5E8D

Q34039724-844A68BE-EDC6-44D6-9C61-18D0CFEDF89B

Q34039724-99E2D858-8C87-4994-8EF6-B914D8F3623D

Q34039724-A81A23A0-A86A-4F7D-A267-839776EA6507

Q34039724-FD354E30-BA5D-4809-8EC0-66024F890256

P2860

Q34039724-099C20FB-1EA9-4C9F-8FFB-A65D083226DE

Q34039724-27A8AA39-21E6-4B76-86D5-88726755253B

Q34039724-2CAE014B-B556-4F25-B1A8-BD915EC6E565

Q34039724-34E26217-020F-49B1-8A49-C6F690E235FF

Q34039724-449CAD5D-6F7C-444F-B1DE-E3E5D8DBF52E

Q34039724-4F7DAA0E-61B6-461D-BEC3-623CA2F36446

Q34039724-5723DF7F-462B-4380-992D-10869F7A55B7

Q34039724-6D571E28-4359-4911-8ED2-F668C445C297

Q34039724-6D96E2D7-E222-450B-91B5-127BD20B7C5C

Q34039724-6DBFF206-311D-4DCC-B91F-7447500FAE3D

P304

Q34039724-C91309C0-0BD9-4BB9-A129-4B28CC686348

P31

Q34039724-539FB3F3-A2EB-4EC0-BABF-C21BC43FACBE

P356

Q34039724-46A86DFC-8A77-429C-954F-53F6628A2CAA

P478

Q34039724-EF8660CD-67E2-466F-BCF1-C698D73BD486

P50

Q34039724-26F1DCEC-1D12-4860-A7CC-2E335574CF1D

Q34039724-C1975571-03DE-4013-AB2D-E587C94380F1

P577

Q34039724-2C096FDE-409B-4E6A-8EC8-D225F071EE5E

P5875

Q34039724-F78FF677-229E-4848-B7DB-0AF2690EC31C

P698

Q34039724-E78C5DBD-9280-46A5-AA99-FBE57A253558

P932

Q34039724-999698BC-6B7B-4391-9BFB-9137FD3F801D

P356

1471-2369-12-53

P1433

P1476

Baseline characteristics of pa ...... ENA observational cohort study

@en

P2093

Alberto Martínez-Castelao

http://www.w3.org/2001/XMLSchema#string

Aleix Cases

http://www.w3.org/2001/XMLSchema#string

Aparna Natarajan

http://www.w3.org/2001/XMLSchema#string

Daniel Batlle

http://www.w3.org/2001/XMLSchema#string

Fernando De Alvaro

http://www.w3.org/2001/XMLSchema#string

José L Górriz

http://www.w3.org/2001/XMLSchema#string

José Luño

http://www.w3.org/2001/XMLSchema#string

Juan J De la Cruz-Troca

http://www.w3.org/2001/XMLSchema#string

Rafael Montes

http://www.w3.org/2001/XMLSchema#string

P2860

A new equation to estimate glomerular filtration rate

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification

Prevalence of chronic kidney disease in the United States

CKD classification based on estimated GFR over three years and subsequent cardiac and mortality outcomes: a cohort study.

Clinical practice. Stage IV chronic kidney disease.

Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure.

Intensive blood-pressure control in hypertensive chronic kidney disease

Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function.

Is nephrology more at ease than oncology with erythropoiesis-stimulating agents? Treatment guidelines and an update on benefits and risks.

P304

53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2369-12-53

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Juan F Navarro-González

P577

2011-10-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51693071

http://www.w3.org/2001/XMLSchema#string

P698

21970625

http://www.w3.org/2001/XMLSchema#string

P932

3203029

http://www.w3.org/2001/XMLSchema#string